Tigertriever® Revascularization Device Produced by Rapid Medical Ltd., an Affiliate Company of MicroPort® NeuroTech, Enters

Shanghai, China – On May 27, 2020, the Tigertriever® Revascularization Device (RD) produced by Rapid Medical Ltd., an Israel-based affiliate company of MicroPort® NeuroTech  Co., Ltd., was granted entry into the Special Review Procedure for Innovative Medical Devices (“Green Path”) with National Medical Products Administration of China (NMPA). Tigertriever® has become the 20th product of MicroPort® or its related companies that have entered the “Green Path” since 2015.

 

In April 2019, MicroPort® NeuroTech entered into a strategic cooperation and capital injection agreement with Rapid Medical Ltd., after which MicroPort® NeuroTech became a shareholder in Rapid Medical Ltd. Rapid Medical is  dedicated to the development of innovative medical devices used in neurovascular treatment. The company’s three main products are Tigertriever®, Comaneci® Remodeling Device and Tigertriever®13 Revascularization Device . The agreement stipulates that MicroPort® NeuroTech has the exclusive commercial rights for the three products in the Greater China region. All the products have been in clinical application in Europe after being granted the CE Mark, with Comaneci® also approved by FDA. MicroPort® NeuroTech is in charge of the application for the entry of Tigertriever® into the “Green Path”. Prior to this, two other products of MicroPort® NeuroTech that have also entered the “Green Path”, including Tubridge® Reconstruction Device which was launched in China in 2018.

 

Tigertriever® is a fully retrievable device intended to restore blood flow in patients experiencing acute ischemic stroke. Unlike any other commercial device, the outer diameter of the mesh is controlled via a handle. In addition, Tigertriever® is the only commercial device that utilizes a one-of-a-kind 3D braided technology to create a large pore size mesh for ideal clot penetration. Tigertriever® is comprised of a collapsible, fully retrievable, fine wire construction mounted on a wire shaft that expands to the vessel diameter. The device is delivered through an intracranial micro catheter. Tigertriever® is manufactured from super elastic Nitinol wire with tantalum core and is fully radiopaque. Its unique design is addressed to overcome the limitations of current devices and to provide optimal patient outcomes.

 

Mr. Roy Xie, President of MicroPort® NeuroTech, said, “Tigertriever® is a new generation stentriever. Currently, there are no devices with the same type of design mechanism as the Tigertriever® in the local market. The entry into the ‘Green Path’ is set to expedite its launch in China. Tigertriever® and the stentriever developed by MicroPort® NeuroTech constitute a dual stent strategy to make the product specifications more comprehensive, reach a wider range of lesion positions, and offer a more diversified pricing. The duo stent strategy aims to provide doctors and patients with more clinical options to create an integrated solution for neurovascular intervention.”